The FDA expanded the indications of elotuzumab (Empliciti, Bristol-Myers Squibb) to include use in combination with pomalidomide (Pomalyst, Celgene) and dexamethasone for the treatment of adults with multiple myeloma (MM) who have received at least two prior therapies, including lenalidomide (Revlimid, Celgene) and a proteasome inhibitor.
“Despite remarkable recent innovations with novel therapies for the treatment of multiple myeloma, many patients still face poor outcomes, and